We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
+34.73%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$612M
AUM Growth
+$82.6M
Cap. Flow
+$22.2M
Cap. Flow %
3.63%
Top 10 Hldgs %
69.92%
Holding
102
New
27
Increased
15
Reduced
11
Closed
43

Top Buys

Rank Stock Value
1
GYRE icon
Gyre Therapeutics
GYRE
+$17.5M
2
ARWR icon
Arrowhead Research
ARWR
+$10.9M
3
ARGX icon
argenx
ARGX
+$6.1M
4
RCKT icon
Rocket Pharmaceuticals
RCKT
+$5.71M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.57M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$14.7M
2
ZGNX
Zogenix, Inc.
ZGNX
+$12M
3
PDSB icon
PDS Biotechnology
PDSB
+$8.84M
4
EVH icon
Evolent Health
EVH
+$5.17M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$4.42M

Sector Composition

Rank Sector Weight
1 Healthcare 61.43%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GKOS icon
51
PUT
Glaukos
GKOS
$10.1B
$617K 0.1%
20,000
-11,000
-35% -$333K
AERI
52
PUT
DELISTED
Aerie Pharmaceuticals
AERI
$543K 0.09%
+10,000
New +$559K
CRSP icon
53
PUT
CRISPR Therapeutics
CRSP
$5.23B
$457K 0.07%
+10,000
New +$413K
TEVA icon
54
PUT
Teva Pharmaceuticals
TEVA
$40.1B
$427K 0.07%
+25,000
New +$488K
ENDP
55
PUT
DELISTED
Endo International plc
ENDP
$356K 0.06%
+60,000
New +$419K
ASXC
56
PUT
DELISTED
Asensus Surgical, Inc.
ASXC
$307K 0.05%
13,846
+5,769
+71% +$132K
MNKD icon
57
PUT
MannKind Corp
MNKD
$1.22B
$302K 0.05%
132,500
-40,000
-23% -$108K
OTLK icon
58
Outlook Therapeutics
OTLK
$180M
$26K ﹤0.01%
182
– –
ACAD icon
59
CALL
Acadia Pharmaceuticals
ACAD
$4.65B
– –
-80,000
Closed -$2.41M
ACAD icon
60
Acadia Pharmaceuticals
ACAD
$4.65B
– –
-90,000
Closed -$2.71M
ACRS icon
61
Aclaris Therapeutics
ACRS
$835M
– –
-92,500
Closed -$2.28M
AGIO icon
62
PUT
Agios Pharmaceuticals
AGIO
$1.89B
– –
-40,000
Closed -$2.29M
ATRA icon
63
PUT
Atara Biotherapeutics
ATRA
$79M
– –
-2,200
Closed -$996K
BCRX icon
64
BioCryst Pharmaceuticals
BCRX
$2.29B
– –
-900,000
Closed -$4.42M
BHC icon
65
CALL
Bausch Health
BHC
$2.41B
– –
-100,000
Closed -$2.08M
CRSP icon
66
CALL
CRISPR Therapeutics
CRSP
$5.23B
– –
-80,000
Closed -$1.88M
EDIT icon
67
CALL
Editas Medicine
EDIT
$425M
– –
-64,000
Closed -$1.97M
EVH icon
68
CALL
Evolent Health
EVH
$350M
– –
-32,500
Closed -$400K
EVH icon
69
Evolent Health
EVH
$350M
– –
-420,000
Closed -$5.17M
EVTC icon
70
PUT
Evertec
EVTC
$2.01B
– –
-55,000
Closed -$751K
EXEL icon
71
CALL
Exelixis
EXEL
$14.1B
– –
-50,000
Closed -$1.52M
FOLD
72
DELISTED
Amicus Therapeutics
FOLD
– –
-43,900
Closed -$632K
LXRX icon
73
PUT
Lexicon Pharmaceuticals
LXRX
$1.11B
– –
-32,500
Closed -$321K
MDXG icon
74
PUT
MiMedx Group
MDXG
$622M
– –
-50,000
Closed -$631K
NKTR icon
75
CALL
Nektar Therapeutics
NKTR
$2.46B
– –
-2,400
Closed -$2.15M
1 2
3
4 5

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
MAM
Maytree Asset Management Hong Kong $141M AUM 114% 1-Year Est. Return
HA
HFG Advisors Cincinatti, Ohio $142M AUM 16.9% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
KCAM
Kagan Cocozza Asset Management Mickleton, New Jersey $142M AUM 12.02% 1-Year Est. Return

Acuta Capital Partners's Q1 2018 Portfolio in Review

As of Q1 2018, Acuta Capital Partners held 102 positions worth $612M, up 16% from $530M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Acuta Capital Partners deployed $22.2M of net new capital in Q1 2018, opening 27 new positions and adding to 15 existing holdings. Its largest new stake was Arrowhead Research: 1,762,206 shares worth $12.7M.

By sector, the portfolio is most concentrated in Healthcare at 61% of assets, up from 52% a quarter earlier.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $14.7M trimmed.

  • Acuta Capital Partners's largest Q1 2018 buy was Arrowhead Research: 1,762,206 shares worth $12.7M.
  • Acuta Capital Partners added most to Gyre Therapeutics in Q1 2018, an estimated $17.5M increase.
  • Acuta Capital Partners's biggest Q1 2018 reduction was Immunomedics Inc, cutting an estimated $14.7M.
  • Acuta Capital Partners fully exited Zogenix, Inc. in Q1 2018, selling an estimated $12M.
  • Acuta Capital Partners's ten largest holdings make up 70% of its $612M portfolio in Q1 2018.
  • Acuta Capital Partners opened 27 new positions and closed 43 in Q1 2018.
  • Acuta Capital Partners's portfolio value rose 16% quarter-over-quarter to $612M.

Based on Acuta Capital Partners's 13F filing for Q1 2018, filed 15 May 2018.